These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37822267)

  • 21. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
    Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluations of assisted reproductive technologies in high-income countries: a systematic review.
    Olive E; Bull C; Gordon A; Davies-Tuck M; Wang R; Callander E
    Hum Reprod; 2024 May; 39(5):981-991. PubMed ID: 38438132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001867. PubMed ID: 15674887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baclofen for alcohol use disorder.
    Minozzi S; Saulle R; Rösner S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
    Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2002; (2):CD001867. PubMed ID: 12076425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.
    Naglich AC; Lin A; Wakhlu S; Adinoff BH
    CNS Drugs; 2018 Jan; 32(1):13-31. PubMed ID: 29273901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
    Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH
    CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
    Votaw VR; Mann K; Kranzler HR; Roos CR; Nakovics H; Witkiewitz K
    Drug Alcohol Depend; 2022 Mar; 232():109257. PubMed ID: 35042096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacotherapy of alcohol withdrawal: update and new developments].
    Soyka M; Rösner S
    Nervenarzt; 2021 Jan; 92(1):57-65. PubMed ID: 32696076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review.
    Sampaio F; Feldman I; Lavelle TA; Skokauskas N
    Eur Child Adolesc Psychiatry; 2022 Nov; 31(11):1655-1670. PubMed ID: 33751229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis.
    Panin F; Peana AT
    Front Pharmacol; 2019; 10():1164. PubMed ID: 31680952
    [No Abstract]   [Full Text] [Related]  

  • 35. Advances in Pharmacotherapy Development: Human Clinical Studies.
    Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
    Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of alcohol use disorder in patients with liver disease.
    Nielsen AS; Askgaard G; Thiele M
    Curr Opin Pharmacol; 2022 Feb; 62():145-151. PubMed ID: 34999372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medications for Alcohol Use Disorder.
    Poorman E; McQuade BM; Messmer S
    Am Fam Physician; 2024 Jan; 109(1):71-78. PubMed ID: 38227873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
    Gastfriend DR
    Ann N Y Acad Sci; 2014 Oct; 1327(1):112-30. PubMed ID: 25236185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
    Konstantelos N; Tourchian N; McCormack D; Lecce P; Tadrous M; Gomes T
    Drug Alcohol Depend; 2023 Jan; 242():109705. PubMed ID: 36463765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quadruple pharmacotherapy for alcohol use disorder tolerable yet insufficient: a case report.
    Terasaki D; Ellinwood A; White D
    Subst Abuse Treat Prev Policy; 2024 Feb; 19(1):18. PubMed ID: 38424567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.